<DOC>
	<DOC>NCT02980198</DOC>
	<brief_summary>This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis</brief_summary>
	<brief_title>Study of IFN-K in Dermatomyositis</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<criteria>Patient newly diagnosed or relapsing with "definite" or "probable" dermatomyositis based on ENMC criteria (2004) Patient with an MMT8 ≤ 120 and/or an MMT5 ≤ 22 Patient requiring corticosteroids (CS) at a dose of 1 mg/Kg or ≤ 70 mg of prednisone equivalent/day or currently receiving CS at a dose of 1 mg/Kg or ≤ 70 mg of prednisone equivalent/day Is a male or female, aged between 18 and 65 years, inclusive, at the time of the screening visit Is highrisk human papilloma virus (HPV) positive by (RTqPCR) on a cervical swab Has cytological abnormalities ≥ HSIL on a cervical swab Is positive for autoantibodies antiNXP2, TIF1ɤ, MDA5 or antisynthetase antibodies Is positive for any malignancy or has a history of any malignancy Has received IV pulse dose CS (≥ 250 mg prednisone equivalent/day) Has received intravenous immunoglobulin (IVIg) Has received potent immunosuppressive drugs such as cyclophosphamide, methotrexate, azathioprine, mycophenolate, cyclosporine A, oral tacrolimus Has received abatacept, anifrolumab, belimumab, TNF antagonists or another registered or investigational biological therapy Has received antiBcell therapy (e.g. rituximab, epratuzumab) Has received any live vaccine Has used any investigational or nonregistered product , or any investigational or nonregistered vaccine Has inflammatory joint or skin disease other than dermatomyositis that may interfere with study assessments Has frequent recurrences of oral or genital herpes simplex lesions Is at high risk of significant infection and/or has any current signs or symptoms of infection at entry or has received intravenous antibiotics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>